Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable ...

Eli Lilly (NYSE:LLY) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 ...

By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...

CVS Caremark will resume covering the weight loss drug Zepbound this year after it removed it from its list of covered ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy now for long term growth. Eli Lilly and Company (NYSE:LLY) ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

A new agreement involving Medicare, Eli Lilly and Novo Nordisk could allow some eligible beneficiaries to access GLP-1 weight ...

Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a strong ...

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several ...

CVS Caremark is adding Zepbound, Eli Lilly’s obesity drug, back to its commercial insurance plan formularies, more than a ...

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...